Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
25 nov. 2024 17h35 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical data, will be presented at the 2024 San...
Arvinas to Participate in Upcoming Investor Conferences
04 nov. 2024 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
30 oct. 2024 07h00 HE
|
Arvinas Inc.
– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be...
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
22 oct. 2024 16h05 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
21 oct. 2024 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Participate in Upcoming Investor Conferences
29 août 2024 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
30 juil. 2024 07h00 HE
|
Arvinas Inc.
– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2-...
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
24 juin 2024 16h37 HE
|
Arvinas Inc.
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage...
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
21 juin 2024 07h00 HE
|
Arvinas Inc.
– Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma – – Preclinical data presented at the...
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
17 juin 2024 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,...